Host |
Mouse |
Klon |
TS106 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
5-FU resistant cancer. |
Verdünnung |
1:50 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human thymidylate synthase |
Lokalisation |
Cytoplasm |
Thymidylate Synthase (TS)
|
Zeta Corporation |
TS106 |
0.1 ml |
Concentrate |
CE/IVD |
Z2199MT |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Thyroid |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
1 ml |
Concentrate |
CE/IVD |
MOB223 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Thyroid |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB223-01 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Thyroid |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB223-05 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Thyroid |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM576 |
-
|
Host |
Mouse |
Klon |
1D4 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Thyroid |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Diagnostic Biosystems |
1D4 |
25 ml |
Ready-to-use |
CE/IVD |
PDM576-25 |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
1ml |
Concentrate |
CE/IVD |
Z2062ML |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
- |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2062MP |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2062MS |
-
|
Host |
Mouse |
Klon |
2H11+6E1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Thyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Purified human thyroglobulin |
Lokalisation |
Cytoplasm |
Thyroglobulin
|
Zeta Corporation |
2H11+6E1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2062MT |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
1 ml |
Concentrate |
CE/IVD |
MOB418 |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
0.1 ml |
Concentrate |
CE/IVD |
MOB418-01 |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
0.5 ml |
Concentrate |
CE/IVD |
MOB418-05 |
-
|
Host |
Mouse |
Klon |
MoAb47 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thyroid |
Verdünnung |
--- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Thyroid Peroxidase (TPO)
|
Diagnostic Biosystems |
MoAb47 |
6 ml |
ready-to-use |
CE/IVD |
PDM418 |
-
|
Host |
Rabbit |
Klon |
SP141 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
IHC-P |
Vorbehandlung |
Citrate pH 6 |
Positivkontrolle |
Thyroid |
Verdünnung |
1:100 |
Thyroid Transcription Factor-1 (TTF-1)
|
Zytomed Systems GmbH |
SP141 |
0.5 ml |
Concentrate |
RUO |
520-4412 |
-
|
Host |
Rabbit |
Klon |
SP141 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
IHC-P |
Vorbehandlung |
Citrate pH 6 |
Positivkontrolle |
Thyroid |
Verdünnung |
1:100 |
Thyroid Transcription Factor-1 (TTF-1)
|
Zytomed Systems GmbH |
SP141 |
1 ml |
Concentrate |
RUO |
520-4414 |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
7 ml |
Ready-to-use |
CE/IVD |
ALI130G7 |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
6 ml |
Ready-to-use |
CE/IVD |
AVI130G |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
0.1 ml |
Concentrate |
CE/IVD |
CM130A |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
0.5 ml |
Concentrate |
CE/IVD |
CM130B |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
1 ml |
Concentrate |
CE/IVD |
CM130C |
-
|
Host |
Mouse |
Klon |
TIA-1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma, tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm (granular) |
TIA-1
|
Biocare Medical |
TIA-1 |
6 ml |
Ready-to-use |
CE/IVD |
PM130AA |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2183ML |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2183MP |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2183MS |
-
|
Host |
Mouse |
Klon |
2G9A10F5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
Lokalisation |
Cytoplasm |
TIA-1
|
Zeta Corporation |
2G9A10F5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2183MT |
-
|
Host |
Rabbit |
Klon |
ZR284 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length of human TIA-1 protein |
Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
1 ml |
Concentrate |
CE/IVD |
Z2599RL |
-
|
Host |
Rabbit |
Klon |
ZR284 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Full-length of human TIA-1 protein |
Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
7 ml |
ready-to-use |
CE/IVD |
Z2599RP |
-
|
Host |
Rabbit |
Klon |
ZR284 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length of human TIA-1 protein |
Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
0.5 ml |
Concentrate |
CE/IVD |
Z2599RS |
-
|
Host |
Rabbit |
Klon |
ZR284 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Full-length of human TIA-1 protein |
Lokalisation |
Cytoplasmatic |
TIA-1
|
Zeta Corporation |
ZR284 |
0.1 ml |
Concentrate |
CE/IVD |
Z2599RT |
-
|
Host |
Rabbit |
Klon |
BLR047F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BLR047F |
0.1 ml |
Concentrate |
CE/IVD |
ACI3243A |
-
|
Host |
Rabbit |
Klon |
BLR047F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BLR047F |
1 ml |
Concentrate |
CE/IVD |
ACI3243C |
-
|
Host |
Mouse |
Klon |
BC41 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BC41 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3254A |
-
|
Host |
Mouse |
Klon |
BC41 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BC41 |
1 ml |
Concentrate |
CE/IVD |
ACI3254C |
-
|
Host |
Rabbit |
Klon |
BLR047F |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BLR047F |
6 ml |
Ready-to-use |
CE/IVD |
API3243AA |
-
|
Host |
Mouse |
Klon |
BC41 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic |
TIGIT
|
Biocare Medical |
BC41 |
6 ml |
Ready-to-use |
CE/IVD |
API3254AA |
-
|
Host |
Mouse |
Klon |
3A4 |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
1 ml |
Concentrate |
RUO |
MOB318 |
-
|
Host |
Mouse |
Klon |
3A4 |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
0.1 ml |
Concentrate |
RUO |
MOB318-01 |
-
|
Host |
Mouse |
Klon |
3A4 |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
0.5 ml |
Concentrate |
RUO |
MOB318-05 |
-
|
Host |
Mouse |
Klon |
3A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
- |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
6 ml |
Ready-to-use |
RUO |
PDM318 |
-
|
Host |
Mouse |
Klon |
3A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
- |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
TIMP-2 (Tissue Inhibitors of Metalloproteinases 2)
|
Diagnostic Biosystems |
3A4 |
25 ml |
Ready-to-use |
RUO |
PDM318-25 |
-
|
Host |
Mouse |
Klon |
TF9-10H10 |
Format |
Purified |
Methode |
F, P, IF, EL, WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Purified apoprotein of human tissue factor |
Tissue Factor
|
Zytomed Systems GmbH |
TF9-10H10 |
100 µg |
Purified |
RUO |
620-0128 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM93 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Synovial sarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
1 ml |
Concentrate |
CE/IVD |
Z2403ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM93 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Synovial sarcoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
7 ml |
Ready-to-use |
CE/IVD |
Z2403MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM93 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Synovial sarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
0.5 ml |
Concentrate |
CE/IVD |
Z2403MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM93 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Synovial sarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human TLE1 fragment (aa 175-338) |
Lokalisation |
Cytoplasm |
TLE1
|
Zeta Corporation |
ZM93 |
0.1 ml |
Concentrate |
CE/IVD |
Z2403MT |
-
|
Host |
Mouse |
Klon |
DBM15.28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Histiocytoma, colon, pancreas |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgM kappa |
Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
1 ml |
Concentrate |
CE/IVD |
MOB502 |
-
|
Host |
Mouse |
Klon |
DBM15.28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Histiocytoma, colon, pancreas |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgM kappa |
Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
0.1 ml |
Concentrate |
CE/IVD |
MOB502-01 |
-
|
Host |
Mouse |
Klon |
DBM15.28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Histiocytoma, colon, pancreas |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgM kappa |
Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
0.5 ml |
Concentrate |
CE/IVD |
MOB502-05 |
-
|
Host |
Mouse |
Klon |
DBM15.28 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Histiocytoma, colon, pancreas |
Verdünnung |
- |
Isotyp |
IgM kappa |
Lokalisation |
Cytoplasm, extracellular |
TNF alpha
|
Diagnostic Biosystems |
DBM15.28 |
6 ml |
Ready-to-use |
CE/IVD |
PDM230 |
-
|